CheckMate 238, l'update a 9 anni sulla terapia adiuvante del melanoma resecato ad alto rischio

[Oncoinfo – Oncology Snapshots: follow us on http://oncoinfo.it] Resected high-risk melanoma: what are the 9-year data from the adjuvant CheckMate 238 trial presented at ESMO 2025? And how is the role of nivolumab being redefined in this patient setting? We asked Paolo Ascierto (Full Professor of Oncology - Federico II University, Director of the Medical Oncology, Melanoma, Oncologic Immunotherapy and Innovative Therapies Complex Unit at the National Cancer Institute – Pascale Foundation, Naples), whom we met at the Berlin conference.